April 11th 2025
ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.
Adding Icosapent Ethyl to Statin Therapy Cuts Stroke Risk, Analysis of REDUCE-IT Trial Finds
March 17th 2021International Stroke Conference 2021: A new analysis of the landmark REDUCE-IT trial found that adding icosapent ethyl to treatment regimens that already include statins further reduces stroke risk.